The FDA has issued a public safety alert after a patient in Europe diagnosed with possible multiple sclerosis (MS) reportedly developed a rare and serious brain infection known as progressive multifocal leukoencephalopathy (PML) after taking the drug Gilenya (fingolimod).
Gilenya is used to treat relapsing forms of MS, a nervous system disease that affects the brain and spinal cord. According to Novartis, the drug’s manufacturer, about 71,000 patients worldwide have been treated with Gilenya.
PML is a rare and serious brain infection caused by the John Cunningham virus that damages the fatty covering of the brain called myelin. PML can cause death or severe disability. The death rate has recently been reported to be about 20%. PML was first noted in patients receiving cancer chemotherapy and later in those infected with HIV.
The patient in question had been on fingolimod for nearly 8 months when PML was diagnosed, according to the Food and Drug Administration. The agency stopped short of saying fingolimod caused the condition. The FDA is working with Novartis to obtain and review all available information about the occurrence.
The FDA reports that this is the first case reported following the administration of Gilenya to a patient who had not previously received Tysabri (natalizumab), an MS drug associated with a higher risk of PML. A series of PML cases seen with natalizumab after the drug was first approved in 2004 led to its temporary removal from the market.
HO&P Fighting Big Pharma
If you have been injured or have lost someone you care about because of defective or dangerous prescription drugs or medical devices, you deserve to have the manufacturer held responsible and to receive proper compensation. Contact us for a free consultation by calling toll-free at 1-877-446-9001 or by filling out the free consultation form on this page to find out more about your legal options.
Case results depend upon a variety of factors unique to each case. Results of other cases do not guarantee or predict a similar result in any future case.